Rockwell Medical (RMTI) Asset Writedowns and Impairment (2018 - 2025)
Rockwell Medical (RMTI) posted Asset Writedowns and Impairment of $68000.0 for Q4 2025, down 61.8% on a QoQ basis from $178000.0 in Q1 2025, and down 84.0% year-over-year from $425000.0 in Q4 2024.
Rockwell Medical (RMTI) Asset Writedowns and Impairment (2018 - 2025) Analysis & Trends
Rockwell Medical's Asset Writedowns and Impairment history runs 8 years deep, the most recent figure standing at $68000.0 for Q4 2025.
- Quarterly Asset Writedowns and Impairment fell 84.0% year-over-year to $68000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $68000.0 (down 88.72% YoY) and the FY2025 annual result came in at $246000.0, down 42.12% from the prior year.
- Asset Writedowns and Impairment was $68000.0 for Q4 2025 at Rockwell Medical, down from $178000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.1 million in Q3 2023 and bottomed at $10000.0 in Q2 2022.
- A 5-year average of $252500.0 and a median of $124500.0 in 2021 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment soared 431.58% — and 2025, when it sank 84.0%.
- Rockwell Medical's Asset Writedowns and Impairment stood at $57000.0 in 2021, then surged by 431.58% to $303000.0 in 2022, then jumped by 262.38% to $1.1 million in 2023, then tumbled by 61.29% to $425000.0 in 2024, then sank by 84.0% to $68000.0 in 2025.
- Business Quant data shows RMTI's Asset Writedowns and Impairment at $68000.0 in Q4 2025, $178000.0 in Q1 2025, and $425000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Rockwell Medical | 27.99 Mn | 4.10 Mn | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 68,000.00 |
| Dec 31, 2025 | 68,000.00 |
| Mar 31, 2025 | 178,000.00 |
| Mar 31, 2025 | 178,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Sep 30, 2023 | 1.10 Mn |
| Sep 30, 2023 | 1.10 Mn |
| Dec 31, 2022 | 303,000.00 |
| Dec 31, 2022 | 303,000.00 |
| Sep 30, 2022 | 297,000.00 |
| Sep 30, 2022 | 297,000.00 |
| Jun 30, 2022 | 10,000.00 |
| Jun 30, 2022 | 10,000.00 |
| Dec 31, 2021 | 57,000.00 |
| Dec 31, 2021 | 57,000.00 |
| Jun 30, 2021 | 18,000.00 |
| Jun 30, 2021 | 18,000.00 |
| Mar 31, 2021 | 71,000.00 |
| Mar 31, 2021 | 71,000.00 |